Date:8/10/2012

are not limited to): (1) the ability of the Company and its subsidiaries to continue as a going concern; (2) the ability of the Company and its subsidiaries to obtain Bankruptcy Court approval with respect to motions in the Chapter 11 cases; (3) the ability of the Company and its subsidiaries to prosecute, develop and consummate one or more plans of reorganization with respect to the Chapter 11 cases; (4) the effects of the bankruptcy filing on the Company and its subsidiaries and the interests of various creditors, equity holders and other constituents; (5) the effects of rulings of the Bankruptcy Court in the Chapter 11 cases and the outcome of the cases in general; (6) the length of time the Company and its subsidiaries will operate under the Chapter 11 cases; (7) risks associated with third-party motions in the Chapter 11 cases, which may interfere with the ability of the Company and its subsidiaries to develop one or more plans of reorganization and consummate such plans once they are developed; (8) the potential adverse effects of the Chapter 11 proceedings on the Company's liquidity or results of operations; (9) the ability to execute the Company's business and restructuring plans; (10) increased legal costs related to the Company's bankruptcy filing and other litigation; (11) that  its Class A Common Stock and Class B Common Stock will be, or will continue to be, traded on the OTCQB Marketplace and whether sufficient volumes and liquidity will develop; and (12) the ability of the Company and its subsidiaries to maintain contracts that are critical to their operation, including to obtain and maintain normal terms with their vendors, customers and service providers and to retain key executives, managers and employees.

This discussion is not exhaustive, but is designed to highlight important factors that may impact our forward-looking statements.

 Because the factors referred to above, as well as the statements included in Part I, Item 1
'/>"/>

SOURCE K-V Pharmaceutical Company Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
2. Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
3. K-V Pharmaceutical "First Day" Motions Approved by U.S. Bankruptcy Court
4. Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results
5. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
6. UCF nanoparticle discovery opens door for pharmaceuticals
7. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
8. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
9. Pharmaceutical, Food Companies Find Presswood Pallet Ideal for BP-Free Transit Packaging
10. Optimer Pharmaceuticals Reports Second Quarter 2012 Financial Results
11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock